Association between albuminuria and prevalent diabetic retinopathy in type 2 diabetes: a cross-sectional study with exploratory analysis by carotid plaque status - Report - MDSpire
Advertisement
Association between albuminuria and prevalent diabetic retinopathy in type 2 diabetes: a cross-sectional study with exploratory analysis by carotid plaque status
Link Between Urinary Albumin Levels and Existing Diabetic Retinopathy in Type 2 Diabetes
Overview
This study investigates the association between urinary albumin-to-creatinine ratio (ACR) and diabetic retinopathy (DR) in patients with type 2 diabetes. The findings indicate that higher lnACR is associated with prevalent DR, although the association was not statistically significant in sensitivity analyses.
Background
Diabetic retinopathy is a major cause of vision loss in adults, and its prevalence is expected to increase significantly. Understanding the relationship between renal markers like ACR and DR is crucial, as both conditions share common microvascular mechanisms.
Data Highlights
Parameter
Value
Participants with DR
95 (18.9%)
Adjusted OR for lnACR and DR
1.291 (95% CI: 1.045–1.595, P = 0.018)
Adjusted PR for lnACR and DR (sensitivity analysis)
1.160 (95% CI: 0.975–1.380, P = 0.094)
Key Findings
95 out of 502 participants had diabetic retinopathy (DR).
Higher lnACR was significantly associated with prevalent DR in adjusted logistic regression.
The association between lnACR and DR was attenuated and non-significant in modified Poisson sensitivity analysis.
Participants with carotid plaque showed a numerically larger association between lnACR and DR, but this was not statistically significant.
No significant interaction was found between carotid plaque status and the lnACR-DR association.
Clinical Implications
Due to the cross-sectional nature of the study, these results should be interpreted cautiously and not used to alter current screening practices.
Conclusion
This study highlights an association between urinary albumin levels and diabetic retinopathy.
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
